Guanfacine and clonidine for ADHD in adults

Guanfacine and clonidine come up often in conversations about non-stimulant ADHD treatment. Both are older blood pressure medicines that act on alpha-2 receptors in the brain, and both have extended-release versions approved for ADHD. The catch for adults: the evidence behind those ADHD approvals comes from children and adolescents. This page explains what the current FDA labels say, what the adult research shows, and why their use for adult ADHD is generally off-label. Labels were checked on October 19, 2026. Nothing here is a recommendation to start or change a medication.

What these medicines are

The Intuniv label describes guanfacine extended-release as "a central alpha2A-adrenergic receptor agonist." Clonidine extended-release products are described as "centrally acting alpha2-adrenergic" agonists. In plain terms, they stimulate alpha-2 receptors, the same action that makes them useful for high blood pressure. Their labels list lower blood pressure, slower heart rate and sleepiness among their main effects.

None of these products is a controlled substance. The Intuniv and clonidine extended-release labels both state the drug "is not a controlled substance and has no known potential for abuse or dependence."

Which versions are approved for what

The Intuniv label is worth reading closely, because it is often misdescribed. Its indication says only "treatment of ADHD as monotherapy and as adjunctive therapy to stimulant medications," with no age range. But its clinical studies section says efficacy "was established in children and adolescents (6 to 17 years)," and its geriatric section says safety and efficacy in older patients "have not been established." No adult trials appear on the label. For that reason this guide, like the overview of ADHD medications approved for adults, does not count guanfacine as adult-approved.

The clonidine extended-release tablet label states that safety and efficacy "have been established in pediatric patients 6 to 17 years of age." The Onyda XR suspension is indicated "in pediatric patients 6 years of age and older." Using any of them for an adult's ADHD is off-label.

The FDA explains that off-label use means using an approved drug in a way its approval does not cover, and that healthcare providers generally may do so when they judge it medically appropriate. Because the FDA has not determined that the drug is safe and effective for that use, it is reasonable to ask the prescriber what evidence supports it in your situation.

What the adult research shows

The adult evidence is thin, especially for clonidine.

• Few adult trials. A 2018 network meta-analysis in Lancet Psychiatry, which searched for double-blind trials through April 2017, reported no adult data for guanfacine or clonidine "because no studies identified by our search tested these two drugs in adults."
• One larger guanfacine trial. A 2020 phase 3 study in Japanese adults (J Clin Psychiatry) found guanfacine extended-release reduced ADHD symptom scores more than placebo over 10 weeks, with an effect size of 0.52. Side effects were frequent: 19.8% stopped because of adverse events, compared with 3.0% on placebo. The most common were sleepiness, thirst, lower blood pressure, dizziness on standing and constipation.
• Tolerability in pooled adult data. A 2025 component network meta-analysis of adult ADHD treatments found guanfacine had lower acceptability than placebo, meaning more people stopped it. Only stimulants and atomoxetine showed benefit on both self-ratings and clinician ratings.
• Guidelines. The UK's NICE guideline NG87 says not to offer guanfacine to adults for ADHD (an off-label use) without advice from a tertiary ADHD service, and mentions clonidine only for certain children, also with tertiary advice.

How US and international guidelines compare is covered in ADHD clinical guidelines for adults.

Why prescribers still consider them

Despite the gaps, these drugs are sometimes discussed for adults when stimulants are not tolerated or not suitable, or as an add-on. The labels support combination use with stimulants in children and adolescents. Whether that applies to a particular adult is a clinical judgment. The general trade-offs are in stimulant vs nonstimulant ADHD medication.

Warnings on the labels

• Low blood pressure, slow heart rate and fainting. Both drugs lower blood pressure and heart rate. The labels ask for checks before starting, after dose changes and periodically, and advise avoiding dehydration and overheating.
• Sleepiness and sedation. Common with both. The labels caution against driving or operating heavy equipment until you know how you respond, and warn about added sedation with other central nervous system depressants. The clonidine tablet label advises avoiding alcohol.
• Heart conduction problems. They may worsen sinus node dysfunction and AV block, especially with other drugs that slow the heart.
• Rebound high blood pressure if stopped suddenly. The Intuniv label warns that abrupt discontinuation can cause clinically significant and persistent rebound hypertension, and hypertensive encephalopathy has been reported. The clonidine tablet label carries a similar warning. These medicines are tapered, not stopped abruptly; plan any change with the prescriber. See stopping ADHD medication.

Intuniv tablets should be swallowed whole, not taken with high-fat meals, and not swapped for immediate-release guanfacine on a milligram-for-milligram basis, because the two release the drug differently.

Common side effects

In pediatric fixed-dose trials, the Intuniv label lists hypotension, somnolence, fatigue, nausea and lethargy as the most common reactions. For clonidine extended-release tablets used alone, the most common were somnolence, fatigue, irritability, nightmares, insomnia, constipation and dry mouth. These figures come from children and adolescents; adults may differ.

Interactions

• Guanfacine and CYP3A4. Guanfacine is mainly cleared by CYP3A4. Strong and moderate inhibitors such as ketoconazole or fluconazole raise levels; inducers such as rifampin or efavirenz lower them.
• Other blood pressure medicines and sedatives add to the effects of both drugs.

More in ADHD medication drug interactions.

Pregnancy and breastfeeding

The Intuniv label says decades of guanfacine use in pregnancy have not identified a drug-associated risk of major birth defects or miscarriage. There are no data on guanfacine in human milk; if an infant is exposed, the label advises watching for sedation, lethargy and poor feeding. NIH LactMed keeps entries on both guanfacine and clonidine.

New York and New Jersey rules

Because neither drug is controlled, the Schedule II rules in New York (10 NYCRR 80.67), New Jersey's in-person requirements for Schedule II stimulants started by telehealth (P.L.2026, c.40) and the DEA telemedicine rules do not apply to them. Stimulant rules are covered in New York's rules for ADHD stimulant prescriptions and New Jersey's.

Questions to ask your prescriber

• Is this use on-label or off-label for me, and what evidence supports it in adults?
• Would it replace my current medicine or be added to it?
• How will we monitor blood pressure, heart rate and sleepiness?
• What is the plan if I need to stop?

Dr. Shershow evaluates adults for ADHD and discusses medication options, including their evidence and label status, as part of a treatment plan. See adult ADHD treatment.